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ORIGINAL ARTICLE
A Tumor Growth Inhibition Model Based on M-Protein
Levels in Subjects With Relapsed/Refractory Multiple
Myeloma Following Single-Agent Carfilzomib Use
F Jonsson1*, Y Ou2, L Claret1, D Siegel3, S Jagannath4, R Vij5, A Badros6, S Aggarwal2 and R Bruno1
Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of
clinical outcomes for multiple cancer types. We present the application of TGI modeling for subjects with multiple myeloma
(MM). Longitudinal time course changes in M-protein data from relapsed and/or refractory MM subjects who received single-
agent carfilzomib in phase II studies (n5 456) were fit to a TGI model. The tumor growth rate estimate was similar to that of
other anti-myeloma agents, indicating that the model is robust and treatment-independent. An overall survival model was
subsequently developed, which showed that early change in tumor size (ECTS) at week 4, Eastern Cooperative Oncology
Group performance status (ECOG PS), hemoglobin, sex, percent bone marrow cell involvement, and number of prior regimens
were significant independent predictors for overall survival (P < 0.001). ECTS based on M-protein modeling could be an early
biomarker for survival in MM following exposure to single-agent carfilzomib.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 711–719; doi:10.1002/psp4.12044; published online 20 November 2015.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  An early sensitive biomarker for predicting important clini-
cal endpoints, such as overall survival in subjects with multiple myeloma, is lacking; its discovery would be beneficial for
the clinical development of new agents. • WHAT QUESTION DID THIS STUDY ADDRESS?  We evaluated whether
tumor growth inhibition modeling based on longitudinal M-protein data can be used to predict overall survival in subjects
with multiple myeloma following exposure to single-agent carfilzomib. • WHAT THIS STUDY ADDS TO OUR KNOWL-
EDGE  This is the first full report to demonstrate the potential for longitudinal M-protein data in predicting overall
survival in subjects with multiple myeloma. • HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERA-
PEUTICS  We demonstrate two key points from our analysis: 1) a model to integrate data across various clinical stud-
ies for the purpose of predicting important clinical endpoints can be developed using longitudinal M-protein data for
multiple myeloma, and 2) prior clinical study data can be leveraged to assist in future clinical development; a model-
based approach, such as the work here, should be considered prior to the initiation of clinical studies. Importantly, overall
survival is an important clinical endpoint in multiple myeloma clinical research. A robust model to predict overall survival
as shown here could encourage the multiple myeloma field to adopt this model-based approach to impact trial design
and increase the success of trial outcome.
Multiple myeloma (MM) is the second most common hema-
tologic malignancy.1 Carfilzomib (Kyprolis, Onyx Pharma-
ceuticals, South San Francisco, CA), a second-generation
proteasome inhibitor, has been investigated in subjects with
MM, other hematologic malignancies, and solid tumors. In
2012, carfilzomib received accelerated approval from the
US Food and Drug Administration for the treatment of sub-
jects with relapsed and refractory MM.2
Carfilzomib is a tetrapeptide epoxyketone-based irreversi-
ble proteasome inhibitor. Proteasomes are part of a major
mechanism by which cells regulate the concentration of
particular proteins and degrade misfolded proteins. Proteins
are tagged for degradation with a small protein called ubiq-
uitin. The result is a polyubiquitin chain bound by the pro-
teasome, allowing it to degrade the tagged protein.3
Proteasome inhibition leads to the accumulation of polyubi-
quitinated protein substrates within cells and induces apo-
ptosis. Carfilzomib is active in bortezomib-resistant tumor
cell lines,4,5 and, as opposed to bortezomib, is highly spe-
cific for inhibiting proteasome activity.6 The improved selec-
tivity of carfilzomib vs. bortezomib may correlate with the
reduced levels of myelosuppression and peripheral neurop-
athy that were observed in animal toxicology and clinical
studies.7
Myeloma is a malignancy of the plasma cell which pro-
duces immunoglobulins (antibodies). A myeloma protein
(M-protein) is an abnormal immunoglobulin fragment or
immunoglobulin light chain produced in excess by an
abnormal clonal proliferation of plasma cells, typically in
MM. This increase in M-protein concentration is a marker
of tumor burden8 and has several deleterious effects on the
body, including impaired immune function, abnormally high
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viscosity (“thickness”) of the blood, and kidney damage. In
subjects with MM, blood serum M-protein levels are part of
the criteria used to assess response according to the
International Myeloma Working Group Uniform Response
Criteria for MM.8 Response classification is based on cate-
gorical criteria, defined by aggregate data, and does not
make optimal use of available longitudinal information for
predicting ultimate clinical benefits. Thus, alternative
approaches that take into account early and longitudinal
dynamics of M-protein (as a marker of tumor burden) in
subjects with MM may represent early biomarkers to predict
clinical benefit.
In the past few years, efforts have been made to develop
longitudinal tumor size (TS) models to assess the value of
tumor growth inhibition (TGI) as a biomarker to quantitate
drug effect. These models have been used to estimate TGI
metrics that could be used as endpoints to inform early
clinical decisions. A TGI model that makes use of all of the
longitudinal TS data has been successfully applied to pre-
dict expected clinical responses and overall survival (OS)
rates in cancer patients from a variety of clinical set-
tings.9–17 The predictive performance of this model-based
approach has been assessed with prospective simulations
of clinical studies in colorectal cancer10 and non-small cell
lung cancer.11,12 Whether this TGI modeling approach can
be used to simulate clinical study outcomes in MM needs
to be further assessed.
Herein, we show for the first time the application of a pre-
viously described TGI model to a surrogate measurement
of tumor growth for MM (M-protein) using data from four
phase II studies of single-agent carfilzomib. We previously
reported preliminary work in subjects with MM.18–22 A TGI
model based on longitudinal M-protein data in subjects with
relapsed or refractory MM who received high-dose (HD)
dexamethasone18 was used to estimate M-protein tumor
burden at week 8 in subjects treated with pomalidomide
and low-dose dexamethasone, which was used as a basis
for OS and progression-free survival (PFS) simulation.19
The objective of this study was to assess whether changes
in M-protein over time could be used to predict clinical end-
points such as OS after carfilzomib treatment. A model for
predicting long-term outcomes based on routine short-term
M-protein measurements may be useful in providing an
early estimate of long-term benefit for MM subjects treated
with carfilzomib or with other investigational treatments.
METHODS
Trials and data
Data were obtained from four phase II studies (PX-171-
003-A0—Part 1, PX-171-003-A1—Part 2, PX-171-004, and
PX-171-005) of single-agent carfilzomib in subjects with
relapsed or relapsed and refractory MM. All studies were
approved by the review boards of participating institutions.
All subjects provided written informed consent.
PX-171-003 was a single-arm, phase I/II trial in subjects
with relapsed and refractory MM (n5 302). In PX-171-003-
A0—Part 1,23 carfilzomib was given as a 2-minute intrave-
nous (i.v.) infusion at 20 mg/m2, twice weekly, during 3
weeks in a 28-day cycle. Premedication dexamethasone
(4 mg) was given prior to all carfilzomib doses during the
first cycle. Study PX-171-003—Part 2 (A1) was the pivotal
study that was the basis for the accelerated regulatory
approval in the US. This study was an open-label, single-
arm phase II study of single-agent carfilzomib in subjects
with relapsed and refractory MM with 2 prior treatments.
Subjects received carfilzomib (i.v. over 2 to 10 minutes) 20/
27 mg/m2 on days 1, 2, 8, 9, 15, and 16 of 28-day cycles
(20 mg/m2 for all doses in cycle 1 only) for up to 12
cycles.24 Dexamethasone 4 mg was given prior to all carfil-
zomib doses during the first cycle and the first dose escala-
tion cycle. A total of 274 subjects from PX-171-003 was
included in the M-protein TGI modeling.
PX-171-004 was an open-label, single-arm, phase II
study of single-agent carfilzomib in subjects with relapsed
and/or refractory MM with between one and three
prior lines of therapy. This study enrolled two cohorts:
bortezomib-treated and bortezomib-naive subjects.
Bortezomib-treated subjects received carfilzomib (i.v. infu-
sion over 2–10 minutes) at the 20-mg/m2 dose (with no
step up to 27 mg/m2) on days 1, 2, 8, 9, 15, and 16 of 28-
day cycles.25 Bortezomib-naive subjects received carfilzo-
mib (i.v. over 2–10 minutes) 20 mg/m2 or 20/27 mg/m2 on
days 1, 2, 8, 9, 15, and 16 of 28-day cycles (20 mg/m2 in
all doses for cycle 1 only) for up to 12 cycles.26 In both
cohorts, premedication dexamethasone 4 mg was given
prior to all carfilzomib doses during the first cycle and the
first dose escalation cycle.25,26 A total of 146 subjects from
PX-171-003 was included in the M-protein TGI modeling.
PX-171-005 was a phase II, open-label, single-arm, mul-
ticenter study designed to assess the effect of baseline
renal impairment on the pharmacokinetics (PK) of carfilzo-
mib in subjects with relapsed or refractory MM after at least
two prior treatment regimens.27 Carfilzomib was adminis-
tered at 15 mg/m2 i.v. on days 1, 2, 8, 9, 15, and 16 of
each 28-day cycle for up to 12 cycles. Dose escalation to
20 mg/m2 at cycle 2 and then to 27 mg/m2 at cycle 3
occurred as appeared to be tolerated. Premedication dexa-
methasone 4 mg was administered prior to each carfilzomib
dose during cycle 1, and could be increased to 40 mg/
week in subjects who failed to achieve at least a partial
response after cycle 2 or a complete response after cycle 4.
Overall, 28 subjects received premedication dexametha-
sone 40 mg/week at varying timepoints after cycle 2. A
total of 36 subjects from PX-171-003 was included in the
M-protein TGI modeling.
Per protocol, M-protein was to be measured at baseline,
on day 15 of cycle 1, day 1 of subsequent cycles, and at
the end of the study. Pooled data from all studies were
used to develop TGI and OS models.
TGI model for M-protein data
We developed a model that accounts for the dynamics of
tumor growth, exposure-driven antitumor drug effect
(Eq. 1), and development of resistance to drug effect with
time (Eq. 2) based on a previously published TGI model.18
Since PK data were not available from all subjects who had
M-protein data, a virtual biophase modeling approach was
used with dose over time as the input function (Eq. 3).28
The TGI model is described by the following equations:
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dy tð Þ
dt
5KL  y tð Þ2DCFZ  tð Þ  KDCFZ  tð Þ  y tð Þ (1)
KDCFZðtÞ5KDCFZ;0  e2kCFZt (2)
dDCFZ tð Þ
dt
5UCFZ tð Þ2KPCFZ  DCFZ tð Þ (3)
yð0Þ5y0 (4)
DCFZð0Þ5UCFZð0Þ (5)
where y(t) is the M-protein concentration at time t with the
value y0 at baseline (i.e., the M-protein level at first mea-
surement, typically a couple of weeks before start of treat-
ment), KL is the M-protein growth rate, KD,CFZ is the
M-protein shrinkage rate due to carfilzomib exposure, and
decreases with time (from KD,CFZ,0 at time 0) with a rate
constant of kCFZ. DCFZ(t) is the amount (dose) of carfilzo-
mib at the site of action with initial value 0. KP,CFZ is the
elimination rate constant from the virtual biophase compart-
ment for carfilzomib, and UCFZ(t) is the input function of car-
filzomib dose over time.
The TGI model was used to estimate early change in
tumor size (ECTS) at the start of week 4 (commencement
of the second cycle) relative to the predicted M-protein con-
centration immediately before the first dose (y[tfd]), as
shown in Eq. 6:
ECTS5
yðweek 4Þ
yðtfdÞ (6)
ECTS based on week 4 was chosen because the goal of
this work was to assess an early marker to predict OS ben-
efit. In addition, there was minimal dropout at week 4, so
the model was able to include data from the majority of
subjects. Subject-level log-normal distributed random
effects were allowed on all of the model parameters to
account for intersubject variability. At baseline, M-protein
did not follow a log-normal distribution (Supplementary
Figure S1 online). The observed baselines with added
residual error were used according to the “B2” method,29
rather than by estimating the individual baselines. No
covariance between the random effects was initially consid-
ered (diagonal covariance matrix), and this model assump-
tion was subsequently checked. Residual variability was
modeled using an additive plus exponential error model.
Model parameters were estimated using nonlinear mixed-
effects modeling program and first-order conditional
estimation with interaction (NONMEM, v. 7.1.0; ICON
Development Solutions, Ellicott City, MD).
Potential covariates were explored graphically using indi-
vidual (post hoc) random effects plotted against covariates.
In a second step, covariates were tested one-by-one using
the stepwise covariate model building feature in Perl
speaks NONMEM.30 Forward inclusion/backward exclusion
was employed, using an inclusion P value of 0.01 and an
exclusion P value of 0.001.
Trends were detected in the exploratory analysis for the
following covariates, which were tested on either M-protein
growth rate (KL) or drug potency (expressed as shrinkage
rate [KD,CFZ]):
• Baseline albumin on KL (<3.5 g/dL taken as the limit of normal)
• Creatinine clearance (mL/min) on KD,CFZ
• Body weight (kg) on KD,CFZ
• ECOG PS (>0) on KL
• Percent plasma cell involvement on KL
• Number of prior regimens (>1, >2) on KL and KD,CFZ
• Number of drugs on KD,CFZ
• Bortezomib in last prior regimen (yes/no) on KL
• Lenalidomide in last prior regimen (yes/no) on KL
• Sex on KD,CFZ
• Platelet count (109/L) on KL
The predictive performance of the model was evaluated
using a posterior predictive check (PPC), which uses the
model and the study design to simulate statistics of interest
(ECTS at week 4) of many hypothetical trial replicates
(n5 500, number of replicates limited by computation time
with this model) across parameter uncertainty (for different
replicates), interindividual variability (within replicates), and
residual error. Recorded dosing histories and matching
observed predose M-protein levels were sampled as inputs
to the model. The simulated distribution of all percentiles
were recorded and compared with those observed in the
studies. Observed percentiles were compared with the pos-
terior predictive distributions by the model.
Model for OS
A parametric model for OS was developed. The model
describes the survival time distribution as a function of
covariates. The probability density function that best
described the observed survival times was selected among
normal, log-normal, Weibull, logistic, log-logistic, exponen-
tial and extreme, using differences in Akaike Information
Criteria and goodness-of-fit plots of the alternative models.
Model parameter estimation was performed using the soft-
ware R (v. 2.15.2). The survival model can be considered a
drug-independent model that relates a biomarker response
(ECTS) and prognostic factors (covariates) to a clinical end-
point (OS time).
The following baseline covariates were tested as potential
prognostic factors in addition to ECTS week 4 to capture
treatment effect:
• Creatinine clearance (mL/min)
• >1 prior regimen (yes/no)
• >2 prior regimens (yes/no)
• Predicted M-protein concentration (g/L) at time of first dose, y(tfd)
as shown in Eq. 6
• Prior bortezomib treatment (yes/no)
• Number of previous treatments
• Platelet count (109 cells/L)
• Lymphocytes (109 cells/L)
• Hemoglobin (g/dL)
• Albumin (g/dL)
• Sex
• Percent cell involvement
• ECOG PS >0
Covariate effects were first assessed with a Cox propor-
tional hazard regression model using the coxph function in
Tumor Growth Inhibition Model for Multiple Myeloma
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R v. 2.15.2. In a second step, all candidate covariates were
included in a multivariate fashion using the parametric
model. All covariates were then subjected to a backward
stepwise elimination. At each elimination step, the relative
influence of each remaining covariate on the model was
reevaluated by removing it from the reduced model on an
individual basis using a cutoff at P  0.01. Study effect was
evaluated in the final model after adjustment for covariate
effects. The obtained model was the “final” model.
The survival model was evaluated using a PPC. Survival
times for the same number of subjects as in the pooled
dataset were simulated 1,000 times. Parameter values for
the survival model were sampled from the estimated mean
values and variance-covariance matrix (uncertainty in
parameter estimates). Observed survival distributions were
compared with the posterior predictive distributions by the
model (95% prediction interval [PI]).
RESULTS
Longitudinal TGI model for M-protein
The characteristics of the carfilzomib clinical trials from which
the data came are summarized in Tables 1 and 2. The
median number of prior regimens were 5, 1, and 4 in studies
PX-171-003, PX-171-004, and PX-171-005, respectively.23–27
Among 513 subjects with M-protein data at any timepoint,
456 (87%) had data that could be used to develop the lon-
gitudinal model for M-protein following carfilzomib exposure;
there were 2,735 total observations (median of 5.0 observa-
tions per subject). The remaining subjects had missing pre-
dose/baseline data (n521) or were nonsecretory at the
time of the first dose (n536).
A large range of baseline M-protein values (0.40–98 g/L)
were observed, together with a variety of M-protein profiles
during treatment (a few typical profiles taken at random are
illustrated in Figure 1).
The parameters of the final model are presented in
Table 3. The model includes two covariates: the effect of
baseline platelet count on the M-protein growth rate (KL) and
the effect of number of prior regimens on the M-protein
shrinkage rate for carfilzomib (KD,CFZ). The M-protein growth
parameter KL increases with decreasing baseline platelet
count. The effect is linear and corresponds to an 80% reduc-
tion in growth rate at maximum platelet count in the dataset
and an increased growth rate of 30% at the lowest platelet
count. The elimination rate of drugs from the virtual biophase
(KP,CFZ) was estimated to be 9.94 weeks
21 when estimated
with the basic model without any covariates. However, its rel-
ative standard error was 160%. As the parameter could not
be estimated with precision, it was fixed to the estimate in
subsequent runs. It may be noted that in the previous prelim-
inary model on which the present TGI model18 is based, KP
was fixed to a value found by likelihood profiling. KD,CFZ was
reduced by 40% among subjects with more than one prior
regimen. However, this effect is uncertain, with a relative
standard error of 40%. Correlations between the estimates
of the random effects were <0.64 and since this model was
not intended to be used in simulations but rather to estimate
ECTS, a diagonal covariance matrix was kept for the final
model. The final NONMEM control file is given in the Sup-
plementary Information online. The model was evaluated
using standard goodness-of-fit plots.
The dexamethasone effect is negligible at doses
<20 mg, and there were too few subjects who received HD
to estimate it.
Table 1 Carfilzomib phase II clinical trial characteristics
Study MM status Prior therapy
Carfilzomib
dosinga N (total)
N (used in model
development) N (observations) Reference
PX-171-003-A0 Relapsed and
refractory
2 regimens;
responded to
first-line and
refractory to
most recent
20 mg/m2 43 39 152 21
PX-171-003-A1b Relapsed and
refractory
2 regimens;
responded to 1
and refractory to
most recent
20/27c mg/m2 259 235 1393 22
PX-171-004 Relapsed and/or
refractory
Responded to first-
line; relapsed or
refractory to 1
but 3 regimens
20 or 20/27c mg/m2 162 146 1088 23,24
PX-171-005 Relapsed and/or
refractory with
various levels of
renal
insufficiency
2 regimens;
achieved MR
to 1
15, 20, 27d mg/m2 49 36 102 25
Total 513 456 2735
MM, multiple myeloma; MR, minimal response; N, number of subjects or observations.
aDays 1, 2, 8, 9, 15, and 16 of a 28-day cycle.
bStudy PX-171-003-A1 is the pivotal trial that provided response data that supported an accelerated approval of the US Food and Drug Administration for
carfilzomib in the United States.
c20 mg/m2 in cycle 1, and then 27 mg/m2 thereafter.
dIncreased each cycle as tolerated.
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The TGI model was used to estimate ECTS at the start
of week 4. Week 4 was chosen, as 396 of 456 subjects
(87%) were on study and sampled at that time. In contrast,
at weeks 2, 6, and 8 there were data for 349 (77%), 337
(74%), and 322 (71%) subjects, respectively.
The results of the PPC are shown in Figure 2. The
observed distribution (blue line) is within the 95% prediction
interval (blue envelope) for most of the quantiles.
Model for OS
A parametric model for time to death was developed based
on the 456 subjects used in the TGI model development.
Of those subjects, 157 (34%) died during the study. Esti-
mated median survival was 15.8 months in study PX-171-
003, while it was not reached in the two other studies. A
log-normal distribution best described the survival data, as
previously observed in other cancer types.10,11 The param-
eter estimates for the final multivariate model for OS are
shown in Table 4.
Several statistically significant baseline prognostic factors
for OS were identified. Survival decreased as percent
plasma cell involvement increased; survival increased with
a higher hemoglobin level or when the subject was female.
Survival was also longer in subjects with an ECOG PS of 0
and among subjects with fewer than three prior regimens.
Finally, the probability of survival increased in subjects who
demonstrated more tumor shrinkage at week 4 (decrease
in ECTS) and this effect was independent of baseline prog-
nostic factors. Study effect was highly significant in univari-
ate analysis (P < 0.0001), but no longer in the final model
after adjustment of the covariate effects (P  0.02).
Model evaluation (PPC) indicated that the model had
good performance in simulating the survival distributions.
Observed distributions of each study are within the 95% PI,
with the only exception of the tail of study PX-171-003,
despite large differences across studies that are accounted
for by the covariates in the model (Figure 3). Studies PX-
171-004 and PX-171-005 are not mature and there is cen-
soring at the end of the distribution, but overall there were
a fair number of events in the pooled dataset.
DISCUSSION
Model-based approaches can be used to integrate early
clinical data to enhance learning and reduce the risk of
large and costly confirmatory trials.9–17 Models predictive of
clinical outcome measures (e.g., OS) can be used to sup-
port phase II study design, decisions at the end of phase II,
and phase III planning and execution.15–17 In MM, this is
important since the OS endpoint usually takes a longer
time to mature, and information prior to the OS data read-
out will significantly facilitate efficient design of the clinical
programs. The current work describes the first application
of TGI and OS modeling to M-protein in MM model simula-
tions based on ECTS as early as week 4 (based on
M-protein time course) in conjunction with other baseline
prognostic factors including ECOG PS, hemoglobin, sex,
percent bone marrow cell involvement, and number of prior
regimens, and shows good agreement to the observed OS
data following carfilzomib treatment. This approach, which
could leverage prior knowledge and early or interim clinical
data to support decisions through simulations of late clinical
endpoints (e.g., OS),15–17 has potential to substantially
improve the efficiency of drug development for MM. In this
work, we used a sequential approach for model develop-
ment. We developed the tumor size model first (TGI
model), estimated ECTS, and then developed the OS
model. Joint modeling is theoretically better, as it is estimat-
ing model parameters from a joint likelihood that combines
uncertainty in parameter estimates.14,31 In this work, we
therefore did not take into account the uncertainty in ECTS
prediction in the OS model. Tumor size and OS models
were nevertheless qualified for their respective intended
use (i.e., to estimate ECTS and simulate OS). Further
research is warranted to assess the effect of these
Table 2 Covariate distribution by study
Covariate
PX-171-003
(N5274)
PX-171-004
(N5 146)
PX-171-005
(N5 36)
Race (Caucasian/African
American/other)
194/56/24 109/22/15 25/8/3
Mean age, years (SD) 64 (9.4) 65 (9.6) 66 (9.1)
Mean weight, kg (SD) 79 (19) 82 (19) 84 (19)
Mean CrCl, mL/min (SD) 77 (32) 78 (36) 58 (38)
Mean creatinine, mg/dL (SD) 1.1 (0.39) 1.1 (0.30) 2.0 (1.5)
ECOG PS, n (0/1/2/missing) 70/167/36/1 56/81/8/1 6/22/8/0
Mean percent plasma cell
involvement (SD)
43 (29) 31 (26) 49 (30)
Mean serum b2-microglobulin
(SD)
17 (65) 9 (37) 11 (16)
ISS stage (1/2/3/missing) 67/84/81/42 62/44/30/10 7/9/20/0
Bone marrow transplant,
n (no/yes)
64/210 35/111 13/23
Median number of prior
regimens
5.0 1.0 4.0
Mean number of bortezomib
regimens (SD)
2.0 (1.5) 0.21 (0.71) 2.1 (1.5)
Bortezomib in last regimen,
n (no/yes)
135/139 134/12 14/22
Lenalidomide in last regimen,
n (no/yes)
159/115 83/63 26/10
Thalidomide in last regimen,
n (no/yes)
241/33 118/28 23/13
132/142 57/89 16/20
Mean absolute neutrophil
count, 1023/mL (SD)
4.0 (8.4) 3.1 (5.1) 5.8 (9.5)
Sex, n (male/female) 162/112 86/60 20/16
Mean albumin, g/dL (SD) 3.7 (0.64) 3.9 (0.49) 3.4 (0.73)
Mean ALT, U/L (SD) 26 (24) 26 (15) 23 (15)
Mean AST, U/L (SD) 30 (16) 31 (15) 28 (13)
Mean bilirubin, mg/dL (SD) 0.43 (0.26) 0.43 (0.24) 0.58 (0.23)
Mean hemoglobin, g/dL (SD) 10 (1.5) 11 (1.7) 10 (1.8)
Mean lymphocytes, 1023/
mL(SD)
7.0 (7.7) 2.2 (5.5) 4.5 (9.6)
Mean platelets, 1023/mL (SD) 160 (72) 186 (77) 166 (85)
Mean white blood cells, 1023/
mL (SD)
4.3 (1.7) 4.9 (2.0) 5.0 (1.8)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CrCl, cre-
atinine clearance; ECOG PS, Eastern Cooperative Oncology Group perform-
ance status; ISS, International Staging System; SD, standard deviation.
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respective approaches on model performance based on
both simulated and real data. In addition, a block covari-
ance matrix for the random effects should be considered if
the TGI model is to be used in simulations.
We show that ECTS can be predictive of OS as early as
4 weeks following treatment. The link between ECTS and
OS has been shown in previous studies for MM and other
oncology agents,9–22,32 based on estimated ECTS at a later
timepoint (week 8). The average time to response with car-
filzomib treatment ranges from 1 month (in combination
with lenalidomide) to 2 months (carfilzomib monother-
apy),23–27 so ECTS at week 4 is consistent with the time to
response and mechanism of carfilzomib on disease pro-
gression in MM subjects. In addition to ECTS, other metrics
have been used in the TGI model, including time to tumor
(re)growth or tumor growth rate15 as well as the full time
profile of TGI or other biomarker responses.14 These
longer-term metrics capture the whole duration of drug
action rather than just the early shrinkage. Our findings
regarding ECTS at 4 weeks merit further exploration in MM
studies. Furthermore, a comparison of predictability with
other TGI metrics using early or longer-term dynamic
changes in tumor burden may be considered.
The M-protein growth rate estimate (expressed by KL) in
this study was similar to the one reported for other anti-MM
agents in earlier preliminary work,18 indicating that this
disease-specific parameter in the TGI model for MM is
robust and treatment-independent for relapsed/refractory
subjects. This is very encouraging; the results support the
concept of a disease model for which disease-specific
parameters, such as those related to the progression of
MM, can be identified and are consistent, regardless of the
anti-myeloma treatment. As seen with the case study in
which historical lenalidomide phase III data was success-
fully used in a TGI model to predict PFS and OS in a
phase II study of pomalidomide,19 our work corroborates
the previous model results, which showed that a
compound-independent disease model can be developed
using the framework of the TGI model to leverage prior
data to predict clinical endpoints for MM. Such a disease
model framework can be used to predict clinical benefits
from monotherapy vs. combination therapy. Additional sys-
tematic meta-analyses for other anti-myeloma agents are
needed for the comprehensive development of such
disease-specific progression models for MM. The develop-
ment of this kind of disease model, which requires clinical
datasets from multiple agents, will require a close collabo-
ration between industry and regulatory agencies.
The current work used drug dose (full dosing history) as
the exposure metric to drive drug effect, rather than the PK
data, since PK data were not collected in all subjects. It
would be of value to incorporate systemic exposure (i.e., full
PK profile, area under the curve) into the model, to under-
stand the contribution of PK variability to subjects’ responses
in longitudinal M-protein dynamics with the potential to opti-
mize the dose regimen for anti-myeloma agents. An impor-
tant additional consideration is that the half-life of M-protein
in serum is about 3 weeks. Therefore, there may be a lag
time between changes in M-protein and changes in tumor
burden in subjects with MM. To capture the early treatment
Figure 1 Illustration of model fit to M-protein data in a random selection of subjects.
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effect, a model to describe early dynamic change in serum-
free light chain (sFLC) can be considered.21 sFLC has a
much shorter half-life (2 to 3 hours) and can be routinely
measured using existing assays in subjects with MM. In
addition, a rapid reduction in FLC at day 15 following carfil-
zomib treatment was associated with an increased depth of
response and longer PFS in patients with relapsed and
relapsed and/or refractory MM.33
The clinical outcome in MM is also dependent on subject
baseline characteristics, prior lines of therapy, and prognostic
factors. In addition to an increase of M-protein at week 4,
which indicated a lack of drug effect, this integrated meta-
Table 3 Parameter estimates of the final TGI model for carfilzomib
Estimate RSE (%) IIV RSE (%) Shrinkage (%)
KL at median platelet count (week
21) 0.0283 5.7 0.994 19 22
KD,CFZ (1 prior regimen or less) (mg
21week21) 0.0137 13 0.949 15 24
kCFZ (week
21) 0.107 12 0.814 21 38
KP,CFZ (week
21) 9.94 FIXED NA NA NA
Effect of platelet count on KL (mm
3/week) 20.00265 9.1
Fraction of KD,CFZ among subjects
with >1 prior regimen
0.607 40
r additive (g/L) 1.02 18 NA NA 17
r exponential 0.115 9.3 NA NA 17
IIV, intraindividual variability; KD,CFZ, rate of M-protein decrease induced by carfilzomib; KL, rate of M-protein increase; KP,CFZ, rate of elimination of carfilzomib
from virtual biophase compartment; NA, not available; RSE, relative standard error; SD, standard deviation of intersubject variability; TGI, tumor growth inhibi-
tion; kCFZ, rate constant of disappearance of carfilzomib effect. r, residual error additive and exponential terms.
Figure 2 Posterior predictive check of the final tumor growth inhibition model in studies PX-171-003, PX-171-004, and PX-171-005.
Blue lines and shading represent the observed distribution and 95% prediction intervals, respectively. ECTS, early change in tumor size.
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analysis of multiple studies with carfilzomib identified several
baseline characteristics as significant independent prognos-
tic factors for OS, including the number of prior regimens,
baseline hemoglobin level, percent cell involvement, and
good ECOG PS. Low hemoglobin is a marker of MM severity
and is included in the Durie–Salmon staging system.34 Like-
wise, cell involvement is included in the definition of MM
response criteria for a complete response. Good ECOG PS
has been known to be beneficial to survival in several other
cancer types.11,13 While the covariates of OS identified in this
work have yet to be confirmed by additional studies, ECOG
PS and hemoglobin level were also found to be prognostic of
OS in our preliminary work for a different MM agent.19 The
analysis that was based on the limited phase I/II dataset also
showed that females tended to have a longer OS compared
to males, regardless of drug treatment. However, the limited
phase I/II data may have been confounded by other factors
and has not been confirmed with larger phase III datasets.
With all of the potential covariates affecting OS identified in
subjects with MM, a multivariate OS model and correspond-
ing simulations adjusted for patient characteristics could be a
useful tool prior to the start of the pivotal study to increase the
probability of success of clinical studies.
The current work represents a first step in using a TGI
model as an early biomarker to quantify the effect of carfil-
zomib and to ultimately predict an important clinical end-
point (OS) in subjects with MM. The proposed modeling
Figure 3 Kaplan–Meier plot of overall survival (OS) data (solid line) and 95% prediction intervals (shaded areas, 1,000 simulations) of
the multivariate OS model by carfilzomib study. n, number of subjects; NE, not estimable; Obs, observed; PI, prediction interval; Pred,
predicted.
Table 4 Parameter estimates of the final OS model
Covariates Estimatesa RSE (%) 95% CI P value
Intercept 0.7277 94 (20.0609; 2.06) 0.029
ECTS week 4 21.160 16 (21.52; 20.801) <0.001
Hemoglobin (g/dL) 0.3007 19 (0.188; 0.414) <0.001
Female sex 0.7441 23 (0.403; 1.09) <0.001
ECOG performance
status50
0.7343 28 (0.327; 1.14) <0.001
Percent cell
involvement
20.01070 28 (20.0165; 20.00488) <0.001
<3 prior regimens 0.678 30 (0.280; 1.08) <0.001
Log (scale) 0.3060 20 (0.188; 0.424) <0.001
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ECTS,
early change in tumor size; OS, overall survival; RSE, relative standard error.
Positive/negative values indicate increase/decrease of survival probability.
aEstimates correspond to survival times in months.
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framework assumes that the longitudinal M-protein data will
provide additional insight and granularity for predicting the
ultimate benefits of carfilzomib to subjects compared with
the traditional response category. ECTS at week 4 based
on M-protein modeling has the potential to be an early bio-
marker for survival prediction in MM following exposure to
single-agent carfilzomib. Future application of this modeling
approach warrants further investigation for other agents or
combination regimens for MM.
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